Literature DB >> 7827407

Structural features in heparin which modulate specific biological activities mediated by basic fibroblast growth factor.

M Ishihara1, P N Shaklee, Z Yang, W Liang, Z Wei, R J Stack, K Holme.   

Abstract

The biological activity of basic fibroblast growth factor (bFGF) is influenced greatly by direct binding to heparin and heparan sulphate (HS). Heparin-derived oligosaccharides have been utilized to determine the structural requirements present in the polymer that account for binding to bFGF. We had previously demonstrated that fragments > 6 mer can inhibit the interaction between cell surface heparan sulphate proteoglycan (HSPG) and bFGF, and bFGF-induced proliferation of adrenocortical endothelial (ACE) cells. In contrast, oligosaccharides > 10 mer can enhance the binding of bFGF to its high-affinity receptor or support bFGF-induced mitogenesis in ACE cells (Ishihara et al., J. Biol. Chem., 268, 4675-4683, 1993). We have extended these studies to size- and structure-defined oligosaccharides from heparin, 2-O-desulphated (2-O-DS-) heparin, 6-O-desulphated (6-O-DS-) heparin, carboxy-reduced (CR-) heparin and carboxy-amidomethylsulphonated (AMS-) heparin. Oligosaccharides from these polymers were fractionated on a bFGF-affinity column and were assessed as inhibitors or enhancers of specific bFGF-derived biological activities. The results of these studies indicate that both 2-O-sulphate and the negative charge of the carboxy group [L-iduronic acid (IdoA) residues] are required for specific interactions of heparin-derived oligosaccharides with bFGF and for modulation of bFGF mitogenic activity. In addition, the charge of the carboxy groups in uronic acids can be replaced by other functional groups with a negative charge, such as the amidomethyl sulphonate moiety described here.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7827407     DOI: 10.1093/glycob/4.4.451

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  16 in total

Review 1.  Incorporation of heparin into biomaterials.

Authors:  Shelly E Sakiyama-Elbert
Journal:  Acta Biomater       Date:  2013-09-08       Impact factor: 8.947

2.  FGF-FGFR signaling mediated through glycosaminoglycans in microtiter plate and cell-based microarray platforms.

Authors:  Eric Sterner; Luciana Meli; Seok-Joon Kwon; Jonathan S Dordick; Robert J Linhardt
Journal:  Biochemistry       Date:  2013-12-06       Impact factor: 3.162

3.  Effect of heparin oligomer chain length on the activation of valvular interstitial cells.

Authors:  Sara Pedron; Andrea M Kasko; Carmen Peinado; Kristi S Anseth
Journal:  Biomacromolecules       Date:  2010-06-14       Impact factor: 6.988

4.  Fucoidan in a 3D scaffold interacts with vascular endothelial growth factor and promotes neovascularization in mice.

Authors:  Agung Purnama; Rachida Aid-Launais; Oualid Haddad; Muriel Maire; Diego Mantovani; Didier Letourneur; Hanna Hlawaty; Catherine Le Visage
Journal:  Drug Deliv Transl Res       Date:  2015-04       Impact factor: 4.617

5.  Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts.

Authors:  Maryse Delehedde; Malcolm Lyon; John T Gallagher; Philip S Rudland; David G Fernig
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

6.  Synergism between Wnt3a and heparin enhances osteogenesis via a phosphoinositide 3-kinase/Akt/RUNX2 pathway.

Authors:  Ling Ling; Christian Dombrowski; Kin Mun Foong; Larisa M Haupt; Gary S Stein; Victor Nurcombe; Andre J van Wijnen; Simon M Cool
Journal:  J Biol Chem       Date:  2010-06-14       Impact factor: 5.157

7.  Lack of acidic fibroblast growth factor activation by heparan sulfate species from diabetic rat skin.

Authors:  M C Bourin
Journal:  Glycoconj J       Date:  1997-06       Impact factor: 2.916

8.  Oligomerization reduces heparin affinity but enhances receptor binding of fibroblast growth factor 2.

Authors:  M Safran; M Eisenstein; D Aviezer; A Yayon
Journal:  Biochem J       Date:  2000-01-01       Impact factor: 3.857

9.  Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry.

Authors:  B C Herold; S I Gerber; B J Belval; A M Siston; N Shulman
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells.

Authors:  G C Jayson; J T Gallagher
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.